Navigation Links
New genetic techniques to combat lung cancer
Date:4/25/2008

New results on genetic techniques that are helping doctors diagnose and treat lung cancer were released today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland.

In one report (Abstract No. 81O; Friday 25th April, 16:30), Israeli researchers from Rosetta Genomics (Nasdaq:ROSG), a biotech company developing microRNA-based technologies for diagnostic and therapeutic applications, describe a test that helps make crucial distinctions between types of lung cancer. The researchers show the method can accurately distinguish between squamous and non-squamous forms of non-small-cell lung cancer based on the levels of different microRNA molecules found in tissue samples.

MicroRNAs are short RNA molecules that regulate many cancer-related processes. "Recently, with the launch of new targeted therapies for non-squamous, non-small-cell lung cancer, the importance of accurate, objective diagnosis has taken center stage. The ability of physicians to accurately differentiate squamous from non-squamous NSCLC may be used as important treatment guide," said Dr. Maya Gottfried, member of Rosetta Genomics Medical Advisory Board and head of the Lung Cancer Unit at Meir Medical Center in Kfar Saba, Israel. For example some treatments for non-squamous non-small-cell lung cancer can be deadly in patients with the squamous form of the disease. Researchers expect the test to be approved for use during 2008.

In another report (Abstract No. 106PD; Friday 25th April, 08:00), Italian researchers show that genetic analysis can help identify patients who are at high risk of relapse after surgery to remove lung cancer. Dr. Guido Natoli from Regina Elena National Cancer Institute in Rome reports that the three-gene 'signature' can help oncologists choose the best drug to treat with.

"The results are preliminary, but I think our signature may allow the oncologists to classify patients with stage I non-small-cell lung cancer who underwent curative surgical resection in high or low risk molecular category, beyond conventional predictors," says Dr. Natoli.

His group's test includes the gene LCK, which is an important marker of immune cell anticancer activity, DUSP-6 which regulates a signaling pathway involved in cancer spread, and ERCC1, which is thought to be a significant prognostic and therapeutic biomarker in non-small-cell lung cancer. "By gathering these findings we can improve not only the prognostic stratification of patients, but also the choice of the more appropriate adjuvant drug after surgery," Dr. Natoli said.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Many Parents Share Genetic Test Findings With Kids
2. Genetic predisposition increases childhood asthma risk
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Test Spots Genetic Damage Done by Smoking
5. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
6. Scientists highlight benefits of genetic research in sport, but warn of ethical concerns
7. Genetics Hold Promise, Challenges for Cancer Care
8. Researchers genetically engineer micro-organisms into tiny factories
9. Study Questions Genetic Screening for Treatable Diseases
10. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
11. Genetic variation affects smoking cessation treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Carlos ... problems. He has also continued to spiritually evolve, which is the purpose of everyone ... “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers to ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... athletics. It’s enough to overwork even the sharpest brain. , Power On, a ... healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, a ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... medicine in recent years. The technology is so cutting edge, in fact, the ... protocol for stem cell procedures. However, successful patient outcomes in certain clinical stem ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... services to the largest network of hospitals, health information exchanges, physicians and patients, ... Health Information Technology (ONC-HIT) 2015 Edition Health IT Module Certification via Drummond Group ...
(Date:2/22/2017)... ... , ... South Bend’s Lunkerville, the award-winning TV series that catches real people ... (HOW), a non-profit organization dedicated to helping military veterans relax, rehabilitate, and reintegrate through ... to Lake Denmark, New Jersey, to fish with war veteran Justin Vail from the ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), today announced ... ended December 31, 2016. ... This news release should be read ... discussion and analysis for the years ended December 31, 2016 ... available at www.sedar.com and on the Company,s website ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 astic ... new type of antineoplastic drug aiming at functions at ... stepped in to a new stage. Download ... now, there are nearly four million cases of new ... With aging of population, environmental pollution caused by industrialization ...
(Date:2/22/2017)... NEW YORK , Feb. 22, 2017 /PRNewswire/ ... to the congestive heart failure partnering deals and ... companies. Read the full report: http://www.reportlinker.com/p03605673-summary/view-report.html ... Partnering since 2010 report provides understanding and access ... the world,s leading healthcare companies. - ...
Breaking Medicine Technology: